GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » China Isotope & Radiation Corp (HKSE:01763) » Definitions » 3-Year FCF Growth Rate

China Isotope & Radiation (HKSE:01763) 3-Year FCF Growth Rate : -35.50% (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is China Isotope & Radiation 3-Year FCF Growth Rate?

China Isotope & Radiation's Free Cash Flow per Share for the six months ended in Dec. 2023 was HK$1.29.

During the past 12 months, China Isotope & Radiation's average Free Cash Flow per Share Growth Rate was -90.30% per year. During the past 3 years, the average Free Cash Flow per Share Growth Rate was -35.50% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was -21.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 9 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of China Isotope & Radiation was 17.00% per year. The lowest was -35.50% per year. And the median was 9.20% per year.


Competitive Comparison of China Isotope & Radiation's 3-Year FCF Growth Rate

For the Medical Devices subindustry, China Isotope & Radiation's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


China Isotope & Radiation's 3-Year FCF Growth Rate Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, China Isotope & Radiation's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where China Isotope & Radiation's 3-Year FCF Growth Rate falls into.



China Isotope & Radiation 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.


China Isotope & Radiation  (HKSE:01763) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.


China Isotope & Radiation 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of China Isotope & Radiation's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


China Isotope & Radiation (HKSE:01763) Business Description

Traded in Other Exchanges
N/A
Address
No. 66 Changwa Middle Street, Haidian District, Beijing, CHN, 100089
China Isotope & Radiation Corp is a Chinese company. It has five operating segments: Pharmaceuticals; Radioactive source products; Irradiation; Radiation therapy equipment and related services and Other businesses. Its Pharmaceutical segment is the key revenue driver, which manufactures and sells imaging diagnostic and therapeutic radiopharmaceuticals imaging, UBT diagnostic kits, and test analyzers, and other products. Its radioactive source products segment involves the sale of medical and industrial radioactive source products and technical services. The Group's operations are carried out and majority of the Group's customers are located in the PRC.

China Isotope & Radiation (HKSE:01763) Headlines

No Headlines